Eli Lilly reduced Zepbound vial prices for self-paying patients via LillyDirect, aiming to lower obesity treatment costs and improve access. Price reductions include $50 off the 2.5 mg vial and $100 ...

This is the second time Eli Lilly has cut prices of Zepbound on LillyDirect. The pharmaceutical company said it is making the ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S.

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.

Bariatric doctors who regularly prescribe GLP-1s share how long the worst Ozempic side effects last, and the best ways to ...

Eli Lilly is cutting introductory Zepbound prices again, with the lowest dose now $299 monthly for cash-pay customers, a $50 ...

Calls have been more popular than usual in the options pits. LLY's 50-day call/put volume ratio of 2.23 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

With no evidence base to draw upon, clinicians are sharing strategies to help patients stop taking the new weight-loss drugs ...